Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Trulieve Cannabis (TCNNF) EBITDA (2020 - 2025)

Trulieve Cannabis has reported EBITDA over the past 6 years, most recently at $15.3 million for Q4 2025.

  • Quarterly results put EBITDA at $15.3 million for Q4 2025, up 1069.5% from a year ago — trailing twelve months through Dec 2025 was $143.5 million (up 46.75% YoY), and the annual figure for FY2025 was $196.6 million, up 63.7%.
  • EBITDA for Q4 2025 was $15.3 million at Trulieve Cannabis, down from $42.2 million in the prior quarter.
  • Over the last five years, EBITDA for TCNNF hit a ceiling of $83.6 million in Q2 2021 and a floor of -$291.3 million in Q2 2023.
  • Median EBITDA over the past 5 years was $39.8 million (2023), compared with a mean of $16.2 million.
  • Biggest five-year swings in EBITDA: tumbled 573.07% in 2023 and later skyrocketed 6734.63% in 2025.
  • Trulieve Cannabis' EBITDA stood at -$12.2 million in 2021, then tumbled by 65.89% to -$20.2 million in 2022, then skyrocketed by 66.14% to -$6.8 million in 2023, then surged by 119.15% to $1.3 million in 2024, then skyrocketed by 1069.5% to $15.3 million in 2025.
  • The last three reported values for EBITDA were $15.3 million (Q4 2025), $42.2 million (Q3 2025), and $52.6 million (Q2 2025) per Business Quant data.